We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
226
Neurocrine Biosciences
NBIX
$15.7B
$329K 0.02%
+2,500
New +$332K
CRBP icon
227
CALL
Corbus Pharmaceuticals
CRBP
$211M
$329K 0.02%
+35,000
New +$295K
WVE icon
228
Wave Life Sciences
WVE
$993M
$326K 0.02%
+44,900
New +$585K
KURA icon
229
Kura Oncology
KURA
$1.13B
$325K 0.02%
40,000
– –
KPRX icon
230
Kiora Pharmaceuticals
KPRX
$11.6M
$324K 0.02%
167,941
– –
CORT icon
231
Corcept Therapeutics
CORT
$12.3B
$322K 0.02%
+8,000
New +$299K
UPB
232
Upstream Bio Inc
UPB
$366M
$315K 0.02%
+35,000
New +$630K
KIDS icon
233
OrthoPediatrics
KIDS
$617M
$315K 0.02%
19,845
– –
ANNX icon
234
Annexon
ANNX
$942M
$305K 0.02%
55,000
+7,000
+15% +$39.4K
GERN icon
235
Geron
GERN
$970M
$298K 0.02%
200,000
-136,176
-41% -$207K
JD icon
236
JD.com
JD
$38.8B
$296K 0.02%
10,000
– –
PMVP icon
237
PMV Pharmaceuticals
PMVP
$65.2M
$286K 0.02%
231,008
+130,000
+129% +$165K
TRAW icon
238
Traws Pharma
TRAW
$9.07M
$282K 0.02%
154,098
-333
-0.2% -$626
JBIO
239
Jade Biosciences
JBIO
$1.33B
$281K 0.02%
20,000
-1,000
-5% -$14.5K
RARE icon
240
Ultragenyx Pharmaceutical
RARE
$2.52B
$281K 0.02%
+13,400
New +$302K
PCAPU
241
ProCap Acquisition Corp Unit
PCAPU
$279K 0.02%
26,940
– –
BCAX
242
Bicara Therapeutics
BCAX
$1.55B
$273K 0.02%
13,705
– –
RXST icon
243
RxSight
RXST
$293M
$266K 0.02%
43,250
+21,447
+98% +$178K
PANW icon
244
Palo Alto Networks
PANW
$303B
$257K 0.02%
+1,600
New +$269K
NTLA icon
245
Intellia Therapeutics
NTLA
$1.8B
$250K 0.01%
+19,517
New +$249K
CRWD icon
246
CrowdStrike
CRWD
$224B
$250K 0.01%
+2,560
New +$271K
RBRK icon
247
Rubrik
RBRK
$19.2B
$240K 0.01%
+4,900
New +$281K
RPRX icon
248
Royalty Pharma
RPRX
$27.1B
$240K 0.01%
+5,000
New +$219K
SGRY icon
249
Surgery Partners
SGRY
$1.79B
$238K 0.01%
20,000
– –
LRMR icon
250
Larimar Therapeutics
LRMR
$417M
$237K 0.01%
52,745
-132,944
-72% -$531K
8 9
10
11 12

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.